Last reviewed · How we verify
Trifluridine-tipiracil plus Bevacizumab Alone
Trifluridine-tipiracil plus Bevacizumab Alone is a Small molecule drug developed by Delcath Systems Inc.. It is currently in Phase 2 development. Also known as: Trifluridine-tipiracil, Bevacizumab.
At a glance
| Generic name | Trifluridine-tipiracil plus Bevacizumab Alone |
|---|---|
| Also known as | Trifluridine-tipiracil, Bevacizumab |
| Sponsor | Delcath Systems Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study (PHASE1, PHASE2)
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer (PHASE2)
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease (PHASE2)
- A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma (PHASE2)
- Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC (PHASE2)
- Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC (PHASE2)
- Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer (PHASE1, PHASE2)
- CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trifluridine-tipiracil plus Bevacizumab Alone CI brief — competitive landscape report
- Trifluridine-tipiracil plus Bevacizumab Alone updates RSS · CI watch RSS
- Delcath Systems Inc. portfolio CI
Frequently asked questions about Trifluridine-tipiracil plus Bevacizumab Alone
What is Trifluridine-tipiracil plus Bevacizumab Alone?
Trifluridine-tipiracil plus Bevacizumab Alone is a Small molecule drug developed by Delcath Systems Inc..
Who makes Trifluridine-tipiracil plus Bevacizumab Alone?
Trifluridine-tipiracil plus Bevacizumab Alone is developed by Delcath Systems Inc. (see full Delcath Systems Inc. pipeline at /company/delcath-systems-inc).
Is Trifluridine-tipiracil plus Bevacizumab Alone also known as anything else?
Trifluridine-tipiracil plus Bevacizumab Alone is also known as Trifluridine-tipiracil, Bevacizumab.
What development phase is Trifluridine-tipiracil plus Bevacizumab Alone in?
Trifluridine-tipiracil plus Bevacizumab Alone is in Phase 2.
Related
- Manufacturer: Delcath Systems Inc. — full pipeline
- Also known as: Trifluridine-tipiracil, Bevacizumab
- Compare: Trifluridine-tipiracil plus Bevacizumab Alone vs similar drugs
- Pricing: Trifluridine-tipiracil plus Bevacizumab Alone cost, discount & access